Empreendimentos Pague Menos stock (BRPGMNACNOR3): Q1 earnings show double-digit growth but EPS miss weighs on shares

Empreendimentos Pague Menos reported double-digit revenue and EBITDA growth in Q1 2026, with net income quadrupling and digital sales rising to 22.2% of total, yet the stock dipped slightly after an EPS miss.

Empreendimentos Pague Menos S.A. posted double-digit revenue and EBITDA growth in the first quarter of 2026, with net income quadrupling and digital sales climbing to 22.2% of total revenue, according to its latest earnings release and related commentary from market data providers Marketscreener as of 05/07/2026 and TradingView summary as of 05/07/2026. Revenue rose 14.4% year-on-year to about BRL 4.14 billion, beating consensus by roughly 3%, while net income surged on strong margin expansion and cost discipline.

Despite the positive top-line surprise, the stock traded slightly lower after the release, reflecting an earnings-per-share miss versus analyst expectations, as noted in an earnings-call transcript summary Investing.com as of 05/05/2026. The company highlighted that digital sales now account for more than one-fifth of total revenue, signaling progress in its omnichannel strategy, while investors remain cautious about margin sustainability amid Brazil’s high-inflation and high-interest-rate environment.

As of 05/07/2026, Empreendimentos Pague Menos had a market capitalization of about BRL 2.55 billion, up roughly 5.2% over the prior week, according to TradingView as of 05/07/2026. The shares trade on B3 in São Paulo under the ticker PGMN3, with additional ordinary shares listed as PGMN9, as reported by ADVFN as of 05/07/2026.

By the editorial team – specialized in equity coverage.

At a glance

• Name: Empreendimentos Pague Menos S.A.
• Sector/industry: Health / retail pharmacy
• Headquarters/country: Fortaleza, Brazil
• Core markets: Brazil
• Key revenue drivers: Pharmacy retail network, digital sales, private-label products
• Home exchange/listing venue: B3 (São Paulo), ticker PGMN3
• Trading currency: Brazilian real (BRL)

Empreendimentos Pague Menos: core business model

Empreendimentos Pague Menos S.A. operates as a pharmacy retail chain in Brazil, focusing on value-oriented health and personal-care products for a broad consumer base, according to its investor relations and market profiles Empreendimentos Pague Menos IR as of 05/07/2026 and Alpha Spread as of 05/07/2026. The company runs a nationwide network of drugstores that sell prescription medicines, over-the-counter remedies, personal care items, beauty products and household goods, often at competitive price points.

The chain targets price-sensitive households and leverages private-label brands to enhance margins while maintaining affordability, a strategy that has helped it gain share in Brazil’s fragmented pharmacy sector Ad-hoc-news.de as of 05/07/2026. By combining physical stores with an expanding digital platform, Pague Menos aims to capture both in-store and online demand for essential health and wellness products.

Main revenue and product drivers for Empreendimentos Pague Menos

For Empreendimentos Pague Menos, the main revenue drivers are its pharmacy retail network, growing digital sales and a portfolio of private-label products, as outlined in recent earnings commentary and market summaries TradingView summary as of 05/07/2026 and Ad-hoc-news.de as of 05/07/2026. In Q1 2026, revenue increased 14.4% year-on-year to about BRL 4.14 billion, driven by higher foot traffic, basket size and online penetration.

Digital sales now represent 22.2% of total revenue, up from a lower share in prior quarters, reflecting the success of the company’s e-commerce and app-based initiatives TradingView summary as of 05/07/2026. Private-label products, which typically carry higher margins than branded goods, have also contributed to the quadrupling of net income and improved profitability metrics, even as input costs and logistics expenses remain elevated in Brazil.

Conclusion

Empreendimentos Pague Menos delivered strong double-digit revenue growth and a record net income in Q1 2026, with digital sales now accounting for more than one-fifth of total revenue, signaling progress in its omnichannel strategy Ad-hoc-news.de as of 05/07/2026. The company’s focus on value-oriented offerings and private-label products has helped it gain market share in Brazil’s competitive pharmacy sector.

At the same time, the stock’s modest decline after the earnings release underscores that investors are scrutinizing earnings quality and margin sustainability, particularly in a high-inflation, high-interest-rate environment in Brazil Ad-hoc-news.de as of 05/07/2026. For US investors, the shares offer exposure to Brazilian consumer health demand but also carry currency, macroeconomic and regulatory risks that require careful consideration.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.